 |
|
| Advances in understanding cancer biology are resulting in rapid development of novel treatments that target key molecules. Therapies are becoming increasingly precise and more personalized, resulting in a new wave of immunotherapies for advanced cancers once thought to be intractable. |
|
As biopharma pushes get new immunotherapies to patients quickly, novel delivery approaches are needed to address the increasing complexity in study design, to efficiently find molecular subsets of patients, and to partner with sites experienced and efficient in conducting clinical trials in all therapeutic area. Data, technology, and analytics are more beneficial than ever before to support trial optimization.
We will share how we use insights from real-world data and advanced and predictive analytics to optimize study feasibility, planning, and site selection and how we are able to open sites 21 days after a patient is identified first, saving time and money.
|
|
| Key take-aways: |
|
|
• |
|
QuintilesIMS' integrated platform powers more precise, evidence-based decision-making yielding increased predictability and enhanced study delivery |
|
|
• |
|
Combining data-driven analytics with expertise in clinical research further optimizes oncology trials |
|
|
• |
|
Changing the paradigm of opening a site after a patient is identified makes precision medicine trials less costly and brings more trials to more patients
|
|
|
|
|
|
|
|
| Presenters: |
|
Terry L. Murdock
Vice President and Global Head of the Oncology Center of Excellence, QuintilesIMS
|
|
Natalia Balko
Director, Analytics Center of Excellence, QuintilesIMS
|
Kim Ray
Vice President, Site and Patient Networks, QuintilesIMS
|
|
| Moderator: |
|
Kaylynn Chiarello-Ebner
Managing Editor, Special Projects, Applied Clinical Trials
|
|
|
|
|
|
For technical questions about this webinar,
please contact Kristen Moore at kristen.moore@ubm.com |
|
|
|
| |
|
Contact us at
www.quintilesims.com
|
|
|
|
|
|
